Hogan Lovells represents OptiNose in public offering

Philadelphia, 12 June 2018 – Hogan Lovells advised OptiNose, Inc., a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat, and allergy specialists, in an approximate US$120.2 million public offering led by Jefferies and Piper Jaffray.

The offering consists of 2,875,000 shares being sold by Optinose and 2,875,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately US$60.1 million to Optinose and approximately US$60.1 million to the selling stockholders, after deducting underwriting discounts and before offering expenses. Optinose will not receive any proceeds from the sale of shares by the selling stockholders.

Philadelphia partner Steve Abrams led the Hogan Lovells team, which also included Susan Lee,  Steven Kaufman, Steve Nicolai, John Siemann, and John Sharrar.

About Hogan Lovells

Hogan Lovells is a leading global legal practice providing business-oriented legal advice and high-quality service across its exceptional breadth of practices to clients around the world.

“Hogan Lovells” or the “firm” is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP. For more information, see www.hoganlovells.com.


Back To Listing

Loading data